1. Home
  2. IMUX vs SY Comparison

IMUX vs SY Comparison

Compare IMUX & SY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • SY
  • Stock Information
  • Founded
  • IMUX 2016
  • SY 2013
  • Country
  • IMUX United States
  • SY China
  • Employees
  • IMUX N/A
  • SY N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • SY EDP Services
  • Sector
  • IMUX Health Care
  • SY Technology
  • Exchange
  • IMUX Nasdaq
  • SY Nasdaq
  • Market Cap
  • IMUX 86.3M
  • SY 89.4M
  • IPO Year
  • IMUX N/A
  • SY 2019
  • Fundamental
  • Price
  • IMUX $1.00
  • SY $0.95
  • Analyst Decision
  • IMUX Strong Buy
  • SY Hold
  • Analyst Count
  • IMUX 6
  • SY 1
  • Target Price
  • IMUX $12.67
  • SY $0.80
  • AVG Volume (30 Days)
  • IMUX 913.2K
  • SY 53.3K
  • Earning Date
  • IMUX 02-24-2025
  • SY 03-19-2025
  • Dividend Yield
  • IMUX N/A
  • SY 6.35%
  • EPS Growth
  • IMUX N/A
  • SY 1.45
  • EPS
  • IMUX N/A
  • SY 0.05
  • Revenue
  • IMUX N/A
  • SY $212,139,568.00
  • Revenue This Year
  • IMUX N/A
  • SY $2.13
  • Revenue Next Year
  • IMUX N/A
  • SY $4.64
  • P/E Ratio
  • IMUX N/A
  • SY $19.30
  • Revenue Growth
  • IMUX N/A
  • SY 3.87
  • 52 Week Low
  • IMUX $0.92
  • SY $0.66
  • 52 Week High
  • IMUX $2.11
  • SY $1.42
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 50.39
  • SY 58.73
  • Support Level
  • IMUX $0.92
  • SY $0.91
  • Resistance Level
  • IMUX $0.97
  • SY $0.99
  • Average True Range (ATR)
  • IMUX 0.06
  • SY 0.06
  • MACD
  • IMUX 0.01
  • SY 0.00
  • Stochastic Oscillator
  • IMUX 66.61
  • SY 78.65

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenues from information services fees and reservation services fees from medical aesthetic service providers.

Share on Social Networks: